RemeGen's Antibody-Drug Conjugate Gets FDA Fast Track Designation for Ovarian Cancer

RC88 is under evaluation for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Source link
#RemeGen039s #AntibodyDrug #Conjugate #FDA #Fast #Track #Designation #Ovarian #Cancer